Radioreceptor assay for sirolimus

Clinical Biochemistry

Volumn 29, Issue 5, 1996, Pages 457-460

  Goodyear, Nancy ^a,b   Napoli, Kimberly L ^c   Murthy, Jayasimha N ^a   Kahan, Barry D ^c   Soldin, Steven J ^a,b,d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CATHOLIC UNIVERSITY OF AMERICA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

immunophilins; immunosuppression; radioreceptor assay; rapamycin

Indexed keywords

RAPAMYCIN;

ARTICLE; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; RADIORECEPTOR ASSAY;

EID: 0030270002     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(96)00071-9     Document Type: Article

References (29)

1. 1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975; 28: 721-6.
2. 2. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK506 in vitro. J Antibiot 1987; 40: 1249-56.
3. 3. Morris RE. Mechanisms of action of new immunosuppressive drugs. Ther Drug Monit 1995; 17: 64-9.
4. 4. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185-91.
5. 5. Dumont FJ, Melino MR, Starucil MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144: 1418-24.
6. 6. Morris R. Modes of action of FK506, cyclosporin A, and rapamycin. Trans Proc 1994; 26: 3272-5.
7. 7. Bierer BE. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action. Chem Immunol 1994; 59: 128-55.
8. 8. Kahan BD, Gibbons S, Tejpal N, Stepkowski S, Chou TC. Synergistic interaction of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. Transplantation 1991; 51: 232-9.
9. 9. Murthy JN, Chen Y, Soldin SJ. Identification of a 14 kDa FK506/rapamycin binding immunophilin from calf thymus. Clin Biochem 1994; 27: 357-365.
10. 10. Donnelly JG, Soldin SJ. Purification of a 50-to 58-kDA immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. Trans Proc 1991; 23; 2887-90.
11. 11. Napoli KL, Kahan BD. Sample clean up and high performance liquid chromatography techniques for measurement of whole blood rapamycin concentrations. J Chromatogr 1994; 654: 111-20.
12. 12. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Ther Drug Monit 1992; 14: 138-41.
13. 13. Svensson JO, Brattström C, Säwe J. Determination of Sirolimus (rapamycin) in whole blood by HPLC. Ther Drug Monit 1996 (in press).
14. 14. Goodyear N, Murthy JN, Gallant HL, Yatscoff RW, Soldin SJ. Comparison of binding characteristics of four rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity as measured in the mixed-lymphocyte culture assay. Clin Biochem 1996; 29: 309-13.
15. 15. Christians U, Sattler M, Schiebel HM, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Met Dispos 1992; 20: 186-91.
16. 16. Wang CP, Lim HK, Chan KW, Scatina J, Sisenwine SF. High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving rapamycin (Sirolimus) orally. J Liquid Chromat 1995; 18: 2259-68.
17. 17. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: A specific binding protein for cyclosporine A. Science 1984; 226: 544-7.
18. 18. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758-60.
19. 19. Soldin SJ. Radioreceptor assay for rapamycin, U.S. Patent number 5,372,772.
20. 20. Yatscoff RW, LeGatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit 1993; 15: 478-82.
21. 21. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 209-16.
22. 22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307-10.
23. 23. Soldin SJ. Receptor assays in the clinical laboratory. Clin Biochem 1996; 29: 439-44.
24. 24. Donnelly JG, Soldin SJ. A radioreceptor assay for the measurement of cyclosporine activity: A preliminary report. Ther Drug Monit 1989; 11: 696-700.
25. 25. Soldin SJ, Murthy JN, Chen Y, Donnelly JG, Yatscoff RW. Correlation of two radioreceptor assays and the specific and nonspecific fluorescence polarization immunoassays for cyclosporine with immunosuppression as measured by the mixed lymphocyte culture assay. Trans Proc 1994; 26: 2814-7.
26. 26. Murthy JN, Chen Y, Warty VS, et al. Radioreceptor assay for quantifying FK506 immunosuppressant in whole blood. Clin Chem 1992; 38: 1307-10.
27. 27. Bayer Technicon Immuno 1® System. Vitamin B12 method, October 1994, Method # DA4-1206K94.
28. 28. Bayer Technicon Immuno 1® System. Folate method, July 1995, Method # DA4-121695.
29. 29. Gräsbeck R. Biochemistry and clinical chemistry of vitamin B12 transport and the related diseases. Clin Biochem 1984; 17: 99-107.